NASDAQ · IMTX
Immatics N.V.
$7.31-$0.04 (-0.54%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.1% below the high.
Loading market information…
NASDAQ · TCBP · USD
Stock price, earnings
Quote as of Mar 21, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow TC Biopharm (Holdings) Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.31-$0.04 (-0.54%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.1% below the high.
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.86-$0.05 (-5.91%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
$0.37$0.00 (0.0%)
Seelos Therapeutics, Inc.: Healthcare · Biotechnology.
$0.16+$0.02 (+12.4%)
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
